--- title: "Longeveron (LGVN) news: reverse split, delisting and offering" url: "https://aibio.space/companies/longeveron/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LGVN reverse split, delisting, offering and Nasdaq notice news: Longeveron does a 1-for-10 reverse split to meet Nasdaq's $1 bid minimum. Longeveron Inc." --- LGVN Longeveron Inc. NASDAQ · United States # Longeveron (LGVN) news LGVN reverse split, delisting and offering news Listings · 2026-08-24 ## [Longeveron does a 1-for-10 reverse split to meet Nasdaq's $1 bid minimum](https://aibio.space/news/longeveron-does-1-10-reverse-split-meet-nasdaqs-1-bid-minimum/) The split took effect Aug. 26 and cut Class A shares to about 3.04 million. Three weeks later the company reported that its HLHS trial missed its primary endpoint. ## Latest Longeveron news 1. 2026-03-09 Listings [Longeveron tells Nasdaq it lacks audit committee financial expert after director Kender resigns](https://aibio.space/news/longeveron-tells-nasdaq-lacks-audit-committee-financial-expert-after/) Longeveron told Nasdaq on March 4, 2026 that it was temporarily out of compliance after director Richard Kender resigned from its audit committee. The company had $19.2 million of cash at December 31, 2024, and its annual report projected that cash would last only into the fourth quarter of 2025. 2. 2025-09-26 Listings [Longeveron gets Nasdaq minimum bid price notice, has until March 23, 2026 to regain compliance](https://aibio.space/news/longeveron-gets-nasdaq-minimum-bid-price-notice-has-until-march-23/) Nasdaq notified Longeveron (LGVN) on September 22, 2025 that its Class A common stock missed the $1.00 minimum bid price. The notice does not cause immediate delisting; a second 180-day period may be available. 3. 2025-09-26 Listings [Longeveron gets Nasdaq notice for trading below the $1.00 minimum bid price](https://aibio.space/news/longeveron-gets-nasdaq-notice-trading-below-1-00-minimum-bid-price/) The company has until March 23, 2026 to bring its Class A common stock back above the threshold. The notice has no immediate effect on its listing. 4. 2025-09-19 Financings [Longeveron sets up $10,700,000 at-the-market stock program with H.C. Wainwright](https://aibio.space/news/longeveron-sets-up-10-700-000-market-stock-program-h-c-wainwright/) The size is capped by SEC limits for companies with a public float under $75,000,000. Longeveron's stock last sold at $0.77 on September 18, 2025. ## Longeveron at a glance - **Ticker**: LGVN - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $10.1 million ### Related companies - [MetaVia](https://aibio.space/companies/metavia/) NASDAQ: MTVA - [MBX Biosciences](https://aibio.space/companies/mbx-biosciences/) NASDAQ: MBX - [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB - [UroGen Pharma](https://aibio.space/companies/urogen-pharma/) NASDAQ: URGN - [HCW Biologics](https://aibio.space/companies/hcw-biologics/) NASDAQ: HCWB - [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) NASDAQ: SRRK - [Intensity Therapeutics](https://aibio.space/companies/intensity-therapeutics/) NASDAQ: INTS - [Moderna](https://aibio.space/companies/moderna/) NASDAQ: MRNA ### Also on NASDAQ - [Amgen](https://aibio.space/companies/amgen/) AMGN - [Neuronetics](https://aibio.space/companies/neuronetics/) STIM - [Lucid Diagnostics](https://aibio.space/companies/lucid-diagnostics/) LUCD - [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) SBFM - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) SRPT - [MeiraGTx Holdings](https://aibio.space/companies/meiragtx/) MGTX ## What Longeveron does Longeveron Inc. is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its lead investigational product candidate is laromestrocel, also referred to as Lomecel-B, a proprietary, scalable, allogeneic cellular therapy. The company says laromestrocel has multiple potential modes of action, including pro-vascular, pro-regenerative and anti-inflammatory mechanisms that appear to promote tissue repair and healing, and it describes broad potential applications across a spectrum of disease areas. Since its founding in 2014, the company has focused on building and staffing a current good manufacturing practice manufacturing facility with research and development labs, generating clinical safety and efficacy data, and developing its manufacturing processes. It manufactures its own investigational product candidates for early-phase clinical trials and has initiated enhancements to its Chemistry, Manufacturing and Controls infrastructure to support potential future Biologics License Application submissions. The company states it has no subsidiaries. | Product or program | What it is | Stage | |---|---|---| | Laromestrocel (Lomecel-B) | Proprietary allogeneic cellular therapy with pro-vascular, pro-regenerative and anti-inflammatory mechanisms | Lead investigational product candidate; clinical stage company | Summarised from the company's [10-K filed Mar 17, 2026](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/lgvn-20251231.htm). ## Longeveron annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$12.0 million](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/) | [$8.1 million](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/) | | Net income (loss) | [-$22.7 million](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/) | [-$16.0 million](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/) | | Cash from operations | [-$18.6 million](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/) | [-$13.9 million](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/) | | Cash and equivalents | [$4.7 million](https://www.sec.gov/Archives/edgar/data/1721484/000119312526346794/) | [$19.2 million](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/) | | Short-term investments | | [$0](https://www.sec.gov/Archives/edgar/data/1721484/000095017025066889/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $10.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Longeveron Did Longeveron do a reverse stock split? Our latest story on this, dated Aug 24, 2026: "Longeveron does a 1-for-10 reverse split to meet Nasdaq's $1 bid minimum". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/longeveron-does-1-10-reverse-split-meet-nasdaqs-1-bid-minimum/). Was Longeveron delisted? Our latest story on this, dated Sep 26, 2025: "Longeveron gets Nasdaq minimum bid price notice, has until March 23, 2026 to regain compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/longeveron-gets-nasdaq-minimum-bid-price-notice-has-until-march-23/). Has Longeveron raised money recently? Our latest story on this, dated Sep 19, 2025: "Longeveron sets up $10,700,000 at-the-market stock program with H.C. Wainwright". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/longeveron-sets-up-10-700-000-market-stock-program-h-c-wainwright/). Has Longeveron received a Nasdaq deficiency notice? Our latest story on this, dated Sep 26, 2025: "Longeveron gets Nasdaq notice for trading below the $1.00 minimum bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/longeveron-gets-nasdaq-notice-trading-below-1-00-minimum-bid-price/). What is the ticker symbol of Longeveron? Longeveron Inc. trades under the ticker LGVN on NASDAQ. Where is Longeveron listed? Longeveron Inc. is listed on NASDAQ. What is the SEC CIK of Longeveron? The SEC Central Index Key (CIK) for Longeveron Inc. is 1721484. Its filings are on SEC EDGAR. Which country or territory is Longeveron listed under? Our directory records Longeveron Inc. under United States. What does Longeveron do? Our directory classifies Longeveron Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Longeveron? The ISIN recorded for Longeveron Inc. is US54303L3024. Does aibio.space cover Longeveron? aibio.space lists Longeveron Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Longeveron incorporated? SEC records list its state or country of incorporation as DE. What does Longeveron develop? Longeveron Inc. is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its lead investigational product candidate is laromestrocel, also referred to as Lomecel-B, a proprietary, scalable, allogeneic cellular therapy. What is Laromestrocel (Lomecel-B) from Longeveron? Laromestrocel (Lomecel-B): Proprietary allogeneic cellular therapy with pro-vascular, pro-regenerative and anti-inflammatory mechanisms Stage: Lead investigational product candidate; clinical stage company. Is Longeveron profitable? Longeveron Inc. reported a net loss of $22.7 million for the fiscal year ended Dec 31, 2025, and used $18.6 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Longeveron Members talk about Longeveron (LGVN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Longeveron, newest first. Each line links the filing it comes from. 1. 2026-09-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026099712/ea0305306-8k_longeveron.htm) 2. 2026-08-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026093028/ea030309701ex99-1.htm) 3. 2026-07-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026082786/ea0299696-8k_longeveron.htm) 4. 2026-07-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026075514/ea029715301ex99-1.htm) 5. 2026-05-20 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026059525/ea0289252-04.htm) 6. 2026-05-05 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026052281/ea0289252-01.htm) 7. 2026-03-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026034045/ea0283336-8k_longeveron.htm) 8. 2026-03-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026033501/ea0283108-8k_longeveron.htm) 9. 2026-03-17 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1721484/000119312526110664/lgvn-20251231.htm) 10. 2026-03-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026026930/ea028110001ex99-1.htm) 11. 2026-03-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026024839/ea0280382-8k_longeveron.htm) 12. 2026-03-03 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390026022706/ea0279469-01.htm) 13. 2025-09-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390025092316/ea0258323-8k_longever.htm) 14. 2025-09-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390025089589/ea0257857-424b5_longeveron.htm) 15. 2025-08-04 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390025071302/ea0251483-s1_longeve.htm) 16. 2025-03-14 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1721484/000121390025024114/ea0234488-8k_longeveron.htm) 17. 2025-02-28 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1721484/000095017025029968/lgvn-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LGVN on TradingView](https://www.tradingview.com/symbols/NASDAQ-LGVN/). ## SEC filings and registration - **SEC name**: Longeveron Inc. - **CIK**: 1721484 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: LGVN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1951 NW 7TH AVENUE, MIAMI, FL, 33136 - **Phone**: 305-302-7158 - **Former names**: LONGEVERON LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1721484/000121390026109411/ea0308640-8k_longeveron.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/ea0306147-8k_longeveron.htm) filed 2026-09-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1721484/000121390026099712/ea0305306-8k_longeveron.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1721484/000121390026093028/ea0303097-8k_longeveron.htm) filed 2026-08-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1721484/000121390026091677/ea0302723-8k_longeveron.htm) filed 2026-08-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1721484/000121390026088365/ea0301757-8k_longeveron.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1721484/000119312526346794/lgvn-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1721484/000121390026082786/ea0299696-8k_longeveron.htm) filed 2026-07-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001721484), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Longeveron Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LGVN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Longeveron Inc. - **Ticker**: LGVN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US54303L3024 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LGVN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/longeveron/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Longeveron (LGVN) news: reverse split, delisting and offering", 2026-10-31, https://aibio.space/companies/longeveron/